| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
1 Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, and 2 Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, National Cancer Institute, NIH, Bethesda, Maryland
Paclitaxel (Taxol) and docetaxel (Taxotere) have been shown to inhibit angiogenesis at low concentrations that do not affect cancer cell proliferation. Here, we used rat aortic rings and human umbilical vein endothelial cells to evaluate the influence of their formulation vehicles Cremophor EL and polysorbate 80, as well as serum binding proteins on taxane-mediated antiangiogenesis. The data show that clinically relevant concentrations of the vehicles and binding proteins nullify the antiangiogenic activity of both taxanes. It is suggested that these agents may need to be used at much higher doses than anticipated for effective antiangiogenic chemotherapy.
This article has been cited by other articles:
|
|
 |
|
  E. A. Dubikovskaya, S. H. Thorne, T. H. Pillow, C. H. Contag, and P. A. Wender Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters PNAS, August 26, 2008; 105(34): 12128 - 12133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Bradshaw-Pierce, S. G. Eckhardt, and D. L. Gustafson A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man Clin. Cancer Res., May 1, 2007; 13(9): 2768 - 2776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Salvatorelli, P. Menna, L. Gianni, and G. Minotti Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N.A. Bijman, G. P. van Nieuw Amerongen, N. Laurens, V. W.M. van Hinsbergh, and E. Boven Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol. Cancer Ther., September 1, 2006; 5(9): 2348 - 2357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S.W. Ng, A. Sparreboom, Y. Shaked, C. Lee, S. Man, N. Desai, P. Soon-Shiong, W. D. Figg, and R. S. Kerbel Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel. Clin. Cancer Res., July 15, 2006; 12(14): 4331 - 4338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Salvatorelli, P. Menna, S. Cascegna, G. Liberi, A. M. Calafiore, L. Gianni, and G. Minotti Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 424 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ramaswamy, A. D. Elias, N. T. Kelbick, A. Dodley, M. Morrow, M. Hauger, J. Allen, C. Rhoades, K. Kendra, H. X. Chen, et al. Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients. Clin. Cancer Res., May 15, 2006; 12(10): 3124 - 3129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sparreboom, S. D. Baker, and J. Verweij Paclitaxel Repackaged in an Albumin-Stabilized Nanoparticle: Handy or Just a Dandy? J. Clin. Oncol., November 1, 2005; 23(31): 7765 - 7767. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
